View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

US Tariffs - Broad Tariffs are Highly Unlikely (7pgs)

Following a number of recent events, we discuss in this note what we think is the most likely outcome for the Pharma industry. We show that broad based tariffs on drugs are highly unlikely, that even if it were to happen, the impact of a 20% tariff is

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

US Tariffs - Transfer Pricing Could Negate Impact (6pgs)

We show that Big Pharma would not have to shift a single element of supply chain to the US and can mitigate most, if not all, of a 20% tariff on drugs, just by changing their transfer pricing strategy. In a scenario where the US corporation tax rate falls to 15% but tariffs are 20%, we show that Big Pharma profits would be unchanged, while the US government tax take would more than double. The losers would be low tax jurisdictions like Ireland, but they would get to keep their manufacturing base...

 PRESS RELEASE

EQS-News: CTS EVENTIM – Consistently high growth in revenue and earnin...

EQS-News: CTS Eventim AG & Co. KGaA / Key word(s): Annual Report/Annual Results CTS EVENTIM – Consistently high growth in revenue and earnings (news with additional features) 27.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release CTS EVENTIM – Consistently high growth in revenue and earnings Annual revenue rises to EUR 2.809 billion (+19.1%), marking another record-breaking year. Adjusted EBITDA climbs to EUR 542.2 million (+21.9%). At EUR 1.66, the planned dividend is also at an all-time high. Klaus-Peter Schule...

 PRESS RELEASE

EQS-News: CTS EVENTIM – Anhaltend hohe Dynamik bei Umsatz und Ergebnis

EQS-News: CTS Eventim AG & Co. KGaA / Schlagwort(e): Jahresbericht/Jahresergebnis CTS EVENTIM – Anhaltend hohe Dynamik bei Umsatz und Ergebnis (News mit Zusatzmaterial) 27.03.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung CTS EVENTIM – Anhaltend hohe Dynamik bei Umsatz und Ergebnis Der Jahresumsatz wächst auf 2,809 Milliarden Euro (+ 19,1 %) und markiert damit ein weiteres Rekordjahr. Das Adjusted EBITDA klettert auf 542,2 Millionen Euro (+ 21,9 %). Die geplante Dividende erreicht mit 1,66 Euro je Aktie...

Team Pharma
  • Team Pharma

ODDO : Les fondamentaux face à l’incertitude

Les déboires récents de quelques sociétés du secteur (déceptions de CagriSema de Novo, de l’anti-TIGIT de Roche ou investigations en Chine pour AZN) accompagnés de questionnements sur la politique US ont engendré un derating conduisant à une valorisation faciale attractive : PE 26e de 13.2x. Les publications annuelles des 6 large cap Pharma européennes ont été extrêmement rassurantes confirmant les attentes CT et LT du marché. Avec un BPA en croissance moyenne entre 2024 et 2028 de c10%, le PEG ...

Team Pharma
  • Team Pharma

ODDO : Fundamentals vs uncertainty

The recent setbacks for some sector companies (disappointments over Novo Nordisk’s Cagrisema and Roche’s anti-TIGIT or the investigations in China for AZN) along with question marks over US policy have generated a derating leading to a nominally attractive valuations: P/E 2026e of 13.2x. The full-year earnings reports of the six European large cap pharma companies were extremely reassuring, confirming short- and long-term market expectations. With average expected EPS growth between 2024 and 202...

Zurich Insurance Group AG: 1 director

A director at Zurich Insurance Group AG sold 2,000 shares at 595.738CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch